ワシントンにおける濾胞性リンパ腫の臨床試験
ワシントン内の拠点で、濾胞性リンパ腫に関する19件の研究が参加者を募集しています。
ワシントン内の都市
公式研究テキスト（英語）
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT06542250A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Fred Hutchinson Cancer Research Center, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05006716A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance), Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Swedish Cancer Institute (SCI), Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07101328A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
- Fred Hutchinson Cancer Research Center, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT05765812A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- Research Site, Tacoma
被験者募集中第3相
18歳〜130歳 · 全性別 · 2026/09/21更新 · NCT06549595Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
- Northwest Medical Specialties, Tacoma
被験者募集中第3相
12歳〜100歳 · 全性別 · 2026/09/11更新 · NCT06784752SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Fred Hutch Cancer Center, Seattle
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/28更新 · NCT05303519Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/27更新 · NCT06442475A Study of ARC-02 in B-cell NHL
- Summit Cancer Centers - North Spokane, Spokane
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/26更新 · NCT07691606This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/24更新 · NCT07121946Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中第2相
18歳以上 · 全性別 · 2026/06/04更新 · NCT06948786Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中第2相健康なボランティア歓迎
6 Months · 全性別 · 2026/05/29更新 · NCT04195633A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
- Local Institution - 0143, Vancouver
被験者募集中第3相
18歳以上 · 全性別 · 2026/05/20更新 · NCT06911502Study of SGR-1505 in Mature B-Cell Neoplasms
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/13更新 · NCT05544019A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
- University of Washington-Seattle Cancer Care Alliance, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/01/30更新 · NCT04669171SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Seattle
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Swedish Cancer Institute, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2025/10/02更新 · NCT05780034Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients
- University of Washington Medical Center, Seattle
被験者募集中
18歳以上 · 全性別 · 2021/02/23更新 · NCT02537769ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。